CRESE, UBFC, Besancon, France.
Health Econ. 2022 Nov;31(11):2411-2424. doi: 10.1002/hec.4588. Epub 2022 Aug 25.
We characterize the socially optimal pricing policy inducing the implementation of personalized medicine. As a benchmark, we analyze the first-best allocation and the second-best optimal policy when only one treatment is available. Then, we characterize the optimal policy that a Health Authority can design to induce the firm to bear an investment and testing cost allowing it to tailor treatment to patients' needs. We show how optimal prices increase with treatment quality and effectiveness. We characterize the conditions under which these prices yield higher social welfare than in the benchmark case. Moreover, we address some policy and industrial organization issues and characterize the pricing policy inducing the firm to choose the optimal level of treatment effectiveness.
我们描述了诱导实施个性化医疗的社会最优定价政策。作为基准，我们分析了当只有一种治疗方法可用时的第一最佳分配和第二最佳最优政策。然后，我们描述了卫生当局可以设计的最优政策，以促使企业承担投资和测试成本，使其能够根据患者的需求定制治疗方案。我们展示了最优价格如何随治疗质量和效果的提高而增加。我们描述了这些价格产生比基准情况下更高的社会福利的条件。此外，我们还解决了一些政策和产业组织问题，并描述了诱导企业选择最佳治疗效果水平的定价政策。
